3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lahey Clinic
• Treatments: 3,4-diaminopyridine; 4-Aminopyridine; Amifampridine

Criteria

Inclusion Criteria:

• LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis

• 18 years or older

• Females must have negative pregnancy test and be willing to practice an effective form of birth control

• No prolonged QT syndrome as indicated by baseline EKG

Exclusion Criteria:

• Known sensitivity to 3,4-DIAMINOPYRIDINE

• History of seizures and/or severe asthma